Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Here's Why Collaboration Is Important for Progress in Genitourinary Cancers

September 26th 2021, 2:00pm


It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.

Inside the Shifting Treatment Landscape for Advanced Genitourinary Cancers

September 25th 2021, 2:00pm


In this special issue of CURE®, we spoke with patients and health care providers about fertility issues, treatment advancements and other topics related to kidney, prostate, testicular and bladder cancers.

In Understanding Kidney Cancer Treatments, ‘Knowledge Is Power’

September 21st 2021, 1:00pm


Patients and caregivers of those with kidney cancer can become active members in their care by staying up to date on the latest treatments and medical advances.

Lack of Smoking Data in Bladder, Kidney and Prostate Cancer Clinical Trials May Affect Patient Outcomes

September 17th 2021, 5:00pm


Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.

Novel Combinations Offer New Hope in Kidney Cancer

September 13th 2021, 7:00pm


Immunotherapy and tyrosine kinase inhibitors may potentially change the treatment paradigm for patients with renal cell carcinoma, the most common type of kidney cancer in adults.

Cholesterol-Blocking/Hepatitis C Antiviral Drugs May Work on Kidney Cancer

August 26th 2021, 1:00pm


Inhibiting a cholesterol receptor could prevent a certain type of kidney cancer from growing, according to recent research.

FDA’s Welireg Approval A ‘Complete Game Changer’ for Certain Cancers Associated With VHL Disease

August 24th 2021, 4:00pm


The approval of Welireg, according to an expert at Massachusetts General Hospital, is “extremely important” and will “dramatically” change how certain von Hippel-Lindau-associated cancers are treated.

Keytruda-Lenvima Combo for Advanced Renal Cell Carcinoma Signifies ‘a Great Time for the Field’

August 20th 2021, 1:00pm


Frontline Keytruda plus Lenvima for advanced renal cell carcinoma is an effective treatment with life-prolonging benefits, although patients should be monitored for side effects that can be easily managed.

FDA Approves Welireg for Several Cancers Associated With VHL Disease

August 13th 2021, 3:55pm


The FDA granted approval to Welireg for the treatment of patients with von Hippel-Lindau-associated kidney cancer, CNS hemangioblastomas and pancreatic neuroendocrine tumors.

FDA Approves Keytruda Plus Lenvima for Frontline RCC Treatment

August 12th 2021, 11:22am


Patients on Keytruda/Lenvima lived for an average of 23.9 months without their disease progressing, compared to those on a different treatment, with an average of 9.3 months.